Charles Sanders - BioCryst Pharmaceuticals Independent Director
| BCRX Stock | USD 4.50 0.08 1.75% |
Director
Dr. Charles A. Sanders M.D. has resigned as Independent Director of the Company. effective May 2016. Dr. Sanders has 15 years of executive leadership experience in the pharmaceutical industry. He retired from Glaxo Inc. a pharmaceutical company where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. Before joining Glaxo Dr. Sanders spent eight years with Squibb Corporationration where he held a number of posts including the positions of Vice Chairman Chief Executive Officer of the Science and Technology Group and Chairman of the Science and Technology Committee of the board of directors. Previously Dr. Sanders was General Director of Massachusetts General Hospital Professor of Medicine at Harvard Medical School Chairman of The Commonwealth Fund and Chairman of the New York Academy of Sciences. He is a graduate of Southwestern Medical College of the University of Texas. Dr. Sanders is currently a member of the Institute of Medicine of the National Academy of Sciences. He is also Chairman Emeritus of Project HOPE and Chairman of the Foundation for the National Institutes of Health and past Chairman of the UNC Health Care System. Dr. Sanders currently serves as Chairman and a member of the compensation and governance committees of Biodel Inc. and has previously served as a director of Icagen Inc. and Cephalon Inc. In addition he currently serves on the board of directors of the Center for Strategic and International Studies and the GlaxoSmithKline Foundation. since 2009.
| Age | 82 |
| Tenure | 15 years |
| Address | 4505 Emperor Boulevard, Durham, NC, United States, 27703 |
| Phone | 919 859 1302 |
| Web | https://www.biocryst.com |
BioCryst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1157) % which means that it has lost $0.1157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.52 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 24.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 7.6 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joel Marcus | Atara Biotherapeutics | 69 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| Richard Berman | Biovie Inc | 71 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Peter Kiener | Pieris Pharmaceuticals | 63 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| Thilo Schroeder | Blueprint Medicines Corp | 32 | |
| William Kennedy | TG Therapeutics | 73 | |
| Charles Rowland | Viking Therapeutics | 59 | |
| Mark Jacobson | Axsome Therapeutics | 41 | |
| Stephen Glover | PDS Biotechnology Corp | N/A | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
| David McGirr | X4 Pharmaceuticals | 63 | |
| Richard Levy | Madrigal Pharmaceuticals | 60 | |
| Matthew Sherman | Pieris Pharmaceuticals | 61 | |
| Willard Dere | Seres Therapeutics | 64 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| Julian Adams | Pieris Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 |
BioCryst Pharmaceuticals Leadership Team
Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rob Bennett, Vice President Investor Relations & Operations | ||
| Alane Barnes, VP, General Counsel and Corporate Secretary | ||
| Elliott Berger, VP Affairs | ||
| Stanley Erck, Independent Director | ||
| Robert Ingram, Director | ||
| William MBBS, Chief Officer | ||
| Stephanie Angelini, Chief Officer | ||
| Charles Sanders, Independent Director | ||
| Jon Stonehouse, CEO and President and Executive Director | ||
| Charles Gayer, Senior Officer | ||
| Kenneth Lee, Independent Director | ||
| Stephen Aselage, Director | ||
| William Sheridan, Senior Vice President Chief Medical Officer | ||
| Nancy Hutson, Independent Director | ||
| Yarlagadda Babu, Sr. VP of Drug Discovery | ||
| Fred Cohen, Director | ||
| George Abercrombie, Non-Executive Independent Chairman of the Board | ||
| Thomas Staab, CFO, Senior Vice President Principal Accounting Officer, Treasurer | ||
| Michael Jones, Executive Officer | ||
| Lynne Powell, Senior Vice President Chief Commercial Officer | ||
| John Bluth, IR Contact Officer | ||
| Megan Sniecinski, Chief Business Officer | ||
| Sanj Patel, Director | ||
| Theresa Heggie, Director | ||
| Anthony Doyle, Senior CFO | ||
| MD FAAP, Chief Officer |
BioCryst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 206.15 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 88.10 % | ||||
| Number Of Shares Shorted | 32.25 M | ||||
| Price To Earning | (7.11) X |
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with BioCryst Stock
| 0.69 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against BioCryst Stock
| 0.72 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.48 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.